Anxiolytic use of the known Bromantane molecule — RU2175229C2
Patent disclosure · 2001
- What the patent describes
- Bromantane/Ladasten plus-maze and exploration comparisons in mouse strains with different baseline fear/exploration patterns.
- Reported evidence
- Identifies Ladasten as the known Bromantane molecule and cites earlier psychostimulant certificate 860446 and immunostimulant patent 1826906.
Reported patent results
Findings described in words
The patent reports less fear-related behavior with greater exploration, alongside behavioral activation.
Bromantane/Ladasten plus-maze and exploration comparisons in mouse strains with different baseline fear/exploration patterns.
Population or model Bromantane/Ladasten plus-maze and exploration comparisons in mouse strains with different baseline fear/exploration patterns.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Maze/exploration result | Reduced fear-like response in the high-fear strain and increased activity in the more exploratory strain | No transcribed group means or human anxiety outcome |
| Diazepam comparison | The disclosure describes a different activation/sedation profile | This is a laboratory behavioral distinction, not a clinical noninferiority or safety finding |
Strain-specific animal behavior does not establish broad human anxiety efficacy or absence of stimulant adverse effects. Human clinical records remain separate.
Source for these results ↗ · Reviewed 2026-11-06
Patent claims and provenance
Use. Ladasten anxiolytic-use disclosure; the patent provides a development source rather than independent clinical replication.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2175229C2 ↗ · 2001-10-27
- Earliest priority / filing
- 1999-12-22 / 1999-12-22
- Original applicant / assignee
- Научно-исследовательский институт фармакологии РАМН
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20228716 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Anxiolytic agent
Inventors: С.Б. Середенин; М.А. Яркова; Б.А. Бадыштов; тин Б.М. П; Б.М. Пятин; Н.И. Авдюнина; И.С. Морозов; Т.А. Воронина; Г.Г. Незнамов.
Study limitations and source details
Study limitations
- A new-use patent is not evidence of clinical effectiveness or regulatory status.
- The earlier certificates are cited here; the original documents that would establish priority have yet to be located.
Source details
Original patent text checked, including identity and references to the earlier certificates.
Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.
Sources checked
Citation
S. B. Seredenin, M. A. Yarkova, B. A. Badyshtov, B. M. Pyatin, N. I. Avdyunina, I. S. Morozov, T. A. Voronina, G. G. Neznamov. Anxiolytic use of the known Bromantane molecule — RU2175229C2 Russian patent RU2175229C2